Chemotherapy has remained the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors, have entered the therapeutic landscape for this indication. Regulatory approval of targeted therapies, such as Roche/Genentech/Chugai’s Avastin, AstraZeneca’s Lynparza, Clovis Oncology’s Rubraca, and Tesaro’s Zejula, has changed physicians’ prescription habits and created new dynamics in treatment sequencing. This content explores medical oncologists’ current prescribing practices for ovarian cancer in the United States and analyzes the key factors that drive treatment decisions.
- What is the uptake of Avastin, Lynparza, and Zejula maintenance for treatment of platinum-sensitive cancer patients among surveyed oncologists?
- What is the patient share of key therapies used to treat early-stage and advanced-stage (first to fourthline of therapy) ovarian cancer?
- What are the key drivers and obstacles determining current prescribing of Avastin and PARP inhibitors in advanced-stage ovarian cancer?
- How do drug-treatment rates vary across key ovarian cancer patient populations according to stage of disease and line of therapy?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
Survey of 101 medical oncologists in the United States.
KEY DRUGS COVERED
Avastin, Lynparza, Zejula, Rubraca.
KEY INSIGHTS PROVIDED
- Factors influencing disease management and treatment decisions.
- Drivers and constraints of treatment selection.
- Physician-reported treatment practices and brand-level patient shares.